This is the first report to clarify directly that Evi1-high leukemic cells themselves possess the superior potential to Evi1-low cells in oncogenic self-renewal, which highlights the role of Evi1 as a valuable and a functional marker of CML stem cells. This evidence concerns the gene MECOM and chronic myelogenous leukemia, BCR-ABL1 positive.